Effects of Sinovac-Coronavac and Pfizer-BioNTech mRNA vaccines on choroidal and retinal vascular system.

Publication date: Jul 08, 2023

To evaluate the effects of Sinovac-Coronavac and Pfizer-BioNTech mRNA vaccines on choroidal and retinal vascular system using enhanced depth imaging optical coherence tomography (EDI-OCT) and optical coherence tomography angiography (OCTA). In this prospective cross-sectional study, 63 healthy participants (29 with Pfizer-BioNTech, 34 with Sinovac-CoronaVac) were evaluated after the first dose of vaccination. Vessel density (VD) of the superficial (SCP), deep capillary plexus (DCP) and choriocapillaris (CC) were measured with OCTA. Choroidal thickness (CT) were measured with EDI-OCT. Measurements were performed at the 2 week and the 4 week after vaccinations and compared to pre-vaccination values. Regarding Pfizer-BioNTech vaccination, CT in the subfoveal and nasal region significantly increased between the pre-vaccination and post-vaccination 2 week and then significantly decreased to pre-vaccine values at 4 week. The SCP-VD (whole image, fovea, parafovea, perifovea temporal) variables showed a significant decrease at 2 week. The DCP-VD inferior hemi, parafovea inferior hemi, parafovea inferior variables demonstrated a significant decrease at 2 week. The perifovea DCP-VD variables also showed a significant decrease at 2 week, and these variables returned to pre-vaccination values after 4 weeks. The CC-VD variables showed a significant decrease between pre-vaccine and 2 week post-vaccination. Regarding the Sinovac-CoronaVac vaccination, there was no statistically significant difference in CT and VD values before and after vaccination (p> 0. 05). Our study showed significant alterations in retinal vascular density and CT for the Pfizer-BioNTech vaccine at the 2 week, and these parameters became compatible with pre-vaccination values at the 4 week. In contrast, no differences were observed after the Sinovac-Coronovac vaccination.

Concepts Keywords
Choroidal Pfizer-BioNTech
Ct SARS-CoV-2 vaccines
Mrna Sinovac-Coronavac


Type Source Name
disease VO CoronaVac
disease VO dose
disease VO vaccination
drug DRUGBANK Sulodexide
drug DRUGBANK Sulfachlorpyridazine
disease VO vaccine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *